South Korea's Yuhan Corporation has unveiled promising top-line Phase III data for its novel cancer drug lazertinib in the first-line treatment of epidermal growth factor receptor (EGFR) mutation-positive, advanced non-small cell lung cancer (NSCLC), concluding the drug will be competitive as a monotherapy and raising hopes for a second standard-of-care option for a form of the malignancy seen more frequently in Asia.
The top-line findings from the LASER301 study, presented at the ESMO (European Society for Medical Oncology) Asia Congress held in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?